Salarius Pharmaceuticals Faces Financial Struggles Amid Merger Deal and Delisting Threats

Company Overview

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is a clinical-stage biopharmaceutical company focused on developing cancer treatments addressing dysregulated gene expression. The company has not yet generated any revenue from product sales and has consistently experienced operating losses since its inception.

Recent Developments

• As of March 31, 2025, Salarius faced significant liquidity issues, with cash and cash equivalents totaling $1.8 million.
• The company entered a merger agreement with Decoy Therapeutics on January 10, 2025, with expectations of closing contingent on meeting certain financial benchmarks.
• Salarius has appealed Nasdaq's decision to delist its stock due to non-compliance with minimum equity and stock price standards.

Income Statement Analysis (Q1 2025 vs. Q1 2024)

The following points summarize the financial performance as indicated by the condensed consolidated statements:

• Operating Expenses:
  • Research and Development (R&D) costs decreased to $75,532 from $243,002, reflecting cost-saving measures.
  • General and Administrative (G&A) expenses increased to $1,643,163 from $1,528,613, driven by professional fees associated with the merger.
• Net Loss: The net loss for Q1 2025 was $1,709,533, compared to $1,715,290 in Q1 2024, indicating minor improvement in overall losses.
• Loss Per Share: Loss per share decreased to $(1.03) from $(3.27) due to an increased number of shares after the reverse stock split.

Balance Sheet Insights

• Current Assets: Total current assets decreased from $2,987,562 (Dec 2024) to $2,305,086 (Mar 2025), primarily due to cash reduction.
• Current Liabilities: Current liabilities rose significantly from $1,511,279 to $2,277,526, mainly due to increased amounts payable and accrued liabilities.
• Stockholders' Equity: Total stockholders' equity plummeted from $1,511,695 to $61,866, indicating financial distress.

Cash Flow Analysis

• Net cash used in operating activities decreased to $(1,181,714) from $(1,353,955), reflecting lower operational expenses.
• Net cash provided by financing activities was $545,566 in Q1 2025, driven by equity sales, while Q1 2024 saw negative cash flows from financing activities.

Conclusion

Salarius Pharmaceuticals is in a precarious financial position, facing delisting threats and liquidity challenges amid ongoing efforts to secure a merger and additional funding. The company must effectively manage its remaining cash resources while navigating market compliance issues to survive.